Budesonide/Formoterol Teva Pharma B.V.

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Lataa Pakkausseloste (PIL)
08-12-2021
Lataa Valmisteyhteenveto (SPC)
08-12-2021

Aktiivinen ainesosa:

Budesonide, formoterol fumarate dihydrate

Saatavilla:

Teva Pharma B.V. 

ATC-koodi:

R03AK07

INN (Kansainvälinen yleisnimi):

budesonide, formoterol fumarate dihydrate

Terapeuttinen ryhmä:

Drugs for obstructive airway diseases,

Terapeuttinen alue:

Asthma; Pulmonary Disease, Chronic Obstructive

Käyttöaiheet:

Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) 

Tuoteyhteenveto:

Revision: 2

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2020-04-03

Pakkausseloste

                                47
B. PACKAGE LEAFLET
48
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. 160 MICROGRAMS/4.5 MICROGRAMS,
INHALATION POWDER
budesonide/formoterol fumarate dihydrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Budesonide/Formoterol Teva Pharma B.V. is and what it is used for
2.
What you need to know before you use Budesonide/Formoterol Teva Pharma
B.V.
3.
How to use Budesonide/Formoterol Teva Pharma B.V.
4.
Possible side effects
5.
How to store Budesonide/Formoterol Teva Pharma B.V.
6.
Contents of the pack and other information
1.
WHAT BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS AND WHAT IT IS USED FOR
Budesonide/Formoterol Teva Pharma B.V. contains two different active
substances: budesonide and
formoterol fumarate dihydrate.
•
Budesonide belongs to a group of medicines called
‘corticosteroids’ also known as ‘steroids’. It
works by reducing and preventing swelling and inflammation in your
lungs and helps you to
breathe more easily.
•
Formoterol fumarate dihydrate belongs to a group of medicines called
‘long-acting β
2
adrenoceptor agonists’ or ‘bronchodilators’. It works by
relaxing the muscles in your airways.
This will help to open the airways and help you to breathe more
easily.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS INDICATED FOR USE IN ADULTS
18 YEARS OF AGE AND
OLDER ONLY.
BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. IS NOT INDICATED FOR USE IN
CHILDREN 12 YEARS OF AGE
AND YOUNGER OR ADOLESCENTS 13 TO 17 YEARS OF AGE.
Your 
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms
inhalation powder
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose that leaves the mouthpiece of the
Spiromax) contains 160 micrograms
of budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
This is equivalent to a metered dose of 200 micrograms budesonide and
6 micrograms of formoterol
fumarate dihydrate.
Excipient(s) with known effect:
Each dose contains approximately 5 milligrams of lactose (as
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder.
White powder.
White inhaler with a semi-transparent wine red mouthpiece cover.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years
of age and older only.
Asthma
_ _
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular
treatment of asthma, where use
of a combination (inhaled corticosteroid and long-acting β
2
adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids
and “as needed” inhaled short-acting
β
2
adrenoceptor agonists.
or
-in patients already adequately controlled on both inhaled
corticosteroids and long-acting β
2
adrenoceptor agonists.
COPD
_ _
Symptomatic treatment of patients with COPD with forced expiratory
volume in 1 second
(FEV
1
) < 70% predicted normal (post bronchodilator) and a history of
repeated exacerbations, who
have significant symptoms despite regular therapy with long-acting
bronchodilators.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Asthma _
_ _
Budesonide/Formoterol Teva Pharma B.V. is not intended for the initial
management of asthma.
Budesonide/Formoterol Teva Pharma B.V. is not an appropriate treatment
for the adult patient with
only mild asthma who is not adequately controlled with an inhaled
corticosteroid and “as needed”
inhaled short-acting β

                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto bulgaria 08-12-2021
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 01-01-1970
Pakkausseloste Pakkausseloste espanja 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto espanja 08-12-2021
Pakkausseloste Pakkausseloste tšekki 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto tšekki 08-12-2021
Pakkausseloste Pakkausseloste tanska 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto tanska 08-12-2021
Pakkausseloste Pakkausseloste saksa 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto saksa 08-12-2021
Pakkausseloste Pakkausseloste viro 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto viro 08-12-2021
Pakkausseloste Pakkausseloste kreikka 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto kreikka 08-12-2021
Pakkausseloste Pakkausseloste ranska 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto ranska 08-12-2021
Pakkausseloste Pakkausseloste italia 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto italia 08-12-2021
Pakkausseloste Pakkausseloste latvia 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto latvia 08-12-2021
Pakkausseloste Pakkausseloste liettua 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto liettua 08-12-2021
Pakkausseloste Pakkausseloste unkari 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto unkari 08-12-2021
Pakkausseloste Pakkausseloste malta 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto malta 08-12-2021
Pakkausseloste Pakkausseloste hollanti 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto hollanti 08-12-2021
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 01-01-1970
Pakkausseloste Pakkausseloste puola 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto puola 08-12-2021
Pakkausseloste Pakkausseloste portugali 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto portugali 08-12-2021
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 01-01-1970
Pakkausseloste Pakkausseloste romania 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto romania 08-12-2021
Pakkausseloste Pakkausseloste slovakki 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto slovakki 08-12-2021
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 01-01-1970
Pakkausseloste Pakkausseloste sloveeni 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto sloveeni 08-12-2021
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 01-01-1970
Pakkausseloste Pakkausseloste suomi 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto suomi 08-12-2021
Pakkausseloste Pakkausseloste ruotsi 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto ruotsi 08-12-2021
Pakkausseloste Pakkausseloste norja 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto norja 08-12-2021
Pakkausseloste Pakkausseloste islanti 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto islanti 08-12-2021
Pakkausseloste Pakkausseloste kroatia 08-12-2021
Valmisteyhteenveto Valmisteyhteenveto kroatia 08-12-2021